金凯生科：公司主营小分子CDMO服务

Core Viewpoint - The company, Jinkai Biotechnology, confirmed that its main business of small molecule CDMO services is operating normally in both the US and China, with no impact from current tariff policies [1] Group 1 - The company has production bases in both the US and China [1] - The current tariff policies do not affect the company's business operations [1] - Investors are advised to pay attention to the company's third-quarter report for specific performance details [1]